Melanoma Clinical Trial
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
Summary
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.
Full Description
Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma.
Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies.
Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.
Eligibility Criteria
Inclusion Criteria
≥ 18 years old at the time of informed consent
Ability to provide written informed consent and HIPAA authorization
Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
Willingness to undergo phlebotomy for research blood samples
Exclusion Criteria
Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety
Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Indianapolis Indiana, 46202, United States
How clear is this clinincal trial information?